Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Aprea Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 20 | 24 | +4 |
| Shares | 926.9K | 1.63M | +698.5K (+75.4%) |
| Value | $4.36M | $10.8M | +$6.41M (+147.2%) |
New holders (7)
Institutions that held Aprea Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sphera Funds Management Ltd. | 270,000 | $1.81M | 0.29% |
| Nantahala Capital Management, LLC | 205,760 | $1.38M | 0.13% |
| DAFNA Capital Management LLC | 137,174 | $917.7K | 0.21% |
| HighTower Advisors, LLC | 13,864 | $93.0K | 0.00% |
| NBC Securities, Inc. | 899 | $6.00K | 0.00% |
| FMR LLC | 161 | $1.08K | 0.00% |
| Old Point Trust & Financial Services N A | 50 | $335 | 0.00% |
Sold out (3)
Institutions that held Aprea Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Worth Venture Partners, LLC | 87,169 | $409.7K |
| Walleye Capital LLC | 80,000 | $376.0K |
| JPMorgan Chase & Co | 5 | $24 |